Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 79,372 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Parkinson Disease
Interventions: Nighttime Deep Brain Stimulation with Varying Amplitude Settings; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Behavior, Communication, Language
Interventions: Thirty Million Words- Well Baby, Safety Starts at Home; Behavioral · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 952 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 10
States / cities: Berwyn, Illinois • Chicago, Illinois • Oak Park, Illinois

Conditions: Gout Chronic
Interventions: Pegloticase 8 MG/ML [Krystexxa], MMF, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Suicidal Ideation, Suicide Attempt
Interventions: Brief skills sessions plus EMI skills practice prompts, Ecological momentary assessment (EMA), Treatment as usual (TAU); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Safety After Oral Intake
Interventions: MDI-2517 800mg, Placebo, MDI-2517 1600mg, MDI-2517 2400mg, MDI-2517 3600mg; Drug · Other
Lead sponsor: MDI Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Progressive mCRPC
Interventions: I-131-1095, Enzalutamide; Drug
Lead sponsor: Progenics Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 20
States / cities: Duarte, California • Los Angeles, California • Newport Beach, California + 15 more

Conditions: Depression
Interventions: Continuation phase cognitive therapy, Continuation phase fluoxetine, Continuation phase pill placebo, Acute phase cognitive therapy; Behavioral · Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Dallas, Texas

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Oral Mucositis
Interventions: Aloe Vera Mouthwash, Standard of Care; Dietary Supplement · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 3
States / cities: Oak Lawn, Illinois • Park Ridge, Illinois • Milwaukee, Wisconsin

Conditions: Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma, Endometrial Carcinoma, Cancer of the Endometrium
Interventions: Niraparib; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 6
States / cities: New Brunswick, New Jersey • Newark, New Jersey • Bay Shore, New York + 3 more

Conditions: Atherosclerosis, Cardiovascular Disease, Inflammation, Insulin Resistance, Noninsulin-dependent Diabetes Mellitus
Interventions: Salsalate, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Obesity, Induction of Labor Affected Fetus / Newborn
Interventions: Cefazolin, Placebo, Azithromycin; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Acute Coronary Syndrome, Heart Failure, Depression, Generalized Anxiety Disorder, Panic Disorder
Interventions: Collaborative Care; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Boston, Massachusetts • Salem, Massachusetts

Conditions: Advanced Solid Tumors
Interventions: Epofolate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • New York, New York • Philadelphia, Pennsylvania

Conditions: Low-grade Gliomas
Interventions: Tarceva and Rapamycin; Drug
Lead sponsor: Roger Packer; Other
Eligibility: Up to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cognitive/Functional Effects, Delirium, Depression, Lung Cancer, Radiation Toxicity
Interventions: vitamin E, donepezil hydrochloride, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 15
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 12 more

Conditions: Pancreatic Cancer
Interventions: PBP1510 (400mg/16mL), Gemcitabine (1000 mg/m^2); Drug
Lead sponsor: Prestige Biopharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Immune Globulin Intravenous (Human), 10% Solution, Immune Globulin Subcutaneous (Human), 20% Solution; Biological · Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 2 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 16
States / cities: Irvine, California • Centennial, Colorado • North Palm Beach, Florida + 13 more

Conditions: Neoplasms
Interventions: Pilot of Patient-Centered Oncology Care; Other
Lead sponsor: National Committee for Quality Assurance; Other
Eligibility: 18 Years and older
Enrollment: 125,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Aging, Menopause
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Graft Vs Host Disease, Graft-versus-host-disease
Interventions: Belimumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions: LBH589; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Interventions: EGFR BATs after standard of care chemo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Breast Cancer
Interventions: Exercise Training, Chemo only; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Deep Brain Stimulation Neural Recordings of Varied Stimulation During Sleep in Parkinson's Disease

Thirty Million Words- Well Baby Initiative

REduCing Immunogenicity to PegloticasE (RECIPE) Study

Real-time Intervention for Suicide Risk Reduction

Determine the Relationship Between Circadian Rhythms and Nocturnal Asthma

Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

Cognitive Therapy for Recurrent Depression

Prevention of Oral Mucositis in Adults in With Hematologic Malignancy

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term

Pragmatic Collaborative Care for Cardiac Inpatients With Depression or Anxiety

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)

Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)

Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

Phase 2/3 Study of IGSC, 20% in PIDD

Evaluating the Impact of Patient-Centered Oncology Care

Estrogen Use in Protection From Cognitive Decline

Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma

BATs Treatment for Pancreatic Cancer, Phase Ib/II

Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.